Charles Schwab’s Turnstone Biologics TSBX Stock Holding History

Charles Schwab’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,443	Closed	-$90.2K	–	3682
2024 Q1	$90.2K	Buy	34,443 +19,274	+127%	+$55.2K	﹤0.01%	3314
2023 Q4	$38.6K	Hold	15,169	–	–	﹤0.01%	3426
2023 Q3	$59.8K	Buy	+15,169	New	+$135K	﹤0.01%	3392

Other funds holding TSBX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Charles Schwab's TSBX Position: Q2 2024 in Review

Charles Schwab sold out of Turnstone Biologics (TSBX) in Q2 2024, closing a stake of 34,443 shares — an estimated $90.2K sold.

Charles Schwab first reported a position in TSBX in Q3 2023 and held it in 3 quarters. The position peaked at $90.2K in Q1 2024. 47 funds tracked by Wall St. Rank hold TSBX as of Q2 2024.

Charles Schwab reported no remaining Turnstone Biologics position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 34,443 Turnstone Biologics shares in Q2 2024, an estimated $90.2K.
Charles Schwab first reported a position in Turnstone Biologics in Q3 2023 and held it in 3 quarters.
Charles Schwab's Turnstone Biologics position peaked at $90.2K in Q1 2024.
47 funds tracked by Wall St. Rank held Turnstone Biologics as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.